Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 14, 2013Wed, March 13, 2013Tue, March 12, 2013Mon, March 11, 2013Sun, March 10, 2013Sat, March 9, 2013Fri, March 8, 2013Thu, March 7, 2013Wed, March 6, 2013Tue, March 5, 2013Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Affymax, Inc. To Contact The Firm
Published in Health and Fitness on Friday, March 1st 2013 at 19:00 GMT by Market Wire
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In... -- NEW YORK, March 1, 2013 /PRNewswire/ --
NEW YORK, March 1, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Affymax, Inc. ("Affymax" or the "Company") (NASDAQ: AFFY).
(Logo: [ http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ])
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) 2% of patients taking Affymax's kidney treatment drug Omontys were experiencing hypersensitivity reactions resulting in anaphylaxis, a serious and life-threatening allergic reaction; and (2) 0.02% of those taking Omontys experienced fatal anaphylaxis reactions.
On February 23, 2013, Affymax announced that the U.S. Food and Drug Administration ("FDA") was requiring a total recall of the drug due to reports of anaphylaxis. According to the FDA, "serious and fatal" hypersensitivity reactions had been reported in some patients within 30 minutes of receiving their first doses of the drug by intravenous injection. On this news, the price of Affymax stock declined by more than 85%, closing at $2.42 per share, down $14.10 per share from the prior night's close.
Request more information now by clicking here: [ www.faruqilaw.com/AFFY ]. There is no cost or obligation to you.
Take Action
If you invested in Affymax stock or options between December 8, 2011 and February 22, 2013 and would like to discuss your legal rights, visit [ www.faruqilaw.com/AFFY ]. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [ rgonnello@faruqilaw.com ] or [ fmcconville@faruqilaw.com. ] Faruqi & Faruqi, LLP also encourages anyone with information regarding Affymax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ([ www.faruqilaw.com ]). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[ rgonnello@faruqilaw.com ]
Francis McConville, Esq.
[ fmcconville@faruqilaw.com ]
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
RELATED LINKS
[ http://www.faruqilaw.com ]
